Redesigning

Medicine

AGT uses a proprietary gene delivery platform to rapidly develop patented gene and cell therapies that cure infectious disease, monogenic disorders, and cancers by targeting their genetic root causes.

Redesigning Medicine

AGT uses a proprietary gene delivery platform to rapidly develop patented gene and cell therapies that cure infectious disease, monogenic disorders, and cancers by targeting their genetic root causes.

Gene therapy is a technique that allows doctors to treat a disorder by inserting genes into patients’ cells to mitigate the underlying genetic drivers of disease. Human cells can be re-engineered to create highly-effective hunter/killers of invasive pathogens or cancer cells, or reprogramed to produce secretions that provide potent remedies to other disease conditions. There is strong evidence that this new therapeutic technology may unlock treatments and cures for formerly untreatable or incurable human diseases, such as inherited genetic disorders, infectious diseases, and cancer.

Is the cure for cancer right around the corner?…

Advances in gene technologies and the resulting cures are accelerating exponentially while costs are coming down. If you were in Silicon Valley for the last 35 years, you’d recognize parallels to many previous high-tech “explosions” such as microcomputers, software and the Internet. “Moore’s Law” now applies to drug development and the next big startup could be up in a garage near you! Forget zeroes and ones… A-C-G-T is the new growth area of programming and real-world solutions. Viva la revolution!

Who We Are Replacement Photo

Who We Are:

American Gene Technologies International Inc. (AGT) is a private biotechnology company pursuing cures and treatments for Infectious diseases, cancers and monogenic disorders.
AGT's programs are designed to:

Create immunotherapy for HIV disease with gene modified T cells
Activate innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology
Treat PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation
Advance clinically to provide human proof of concept

What We Do:

For over a decade, AGT has developed, tested and banked thousands of lentiviral vectors that can be adapted to the specific needs of new target diseases. AGT has developed gene therapy for diseases using this rapid gene delivery platform

example-scientists-white-border

Gene Therapies

AGT’s platform allows it to pursue exciting clinical “cures” in large and orphan indications and complex diseases. The company has developed individual, intellectual property protected gene therapeutics that are breakthroughs in medicine.

GENE THERAPY

HIV/AIDS

Immunotherapy for HIV disease with gene modified T cells

IMMUNO-ONCOLOGY

Liver Cancer

Activates innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology

GENE THERAPY

Phenylketonuria (PKU)

Treats PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation

Pipeline

American Gene Technologies™ (AGT) is building a rich product pipeline based on its lentiviral vector platform. Our three lead programs are well into the laboratory phase and scheduled to move into the clinic over the coming months.

revised-pipeline-dec-2018

Our Executive Team

American Gene Technologies™ (AGT) is building a rich product pipeline based on its lentiviral vector platform. Our three leading therapeutics are well into the laboratory phase and scheduled to move into the clinical phase over the course of the next 6-18 months. AGT is in the process of testing and commercializing genetic medicines that will cure or halt the progression of several major diseases.

Jeffrey A. Galvin<br/>
CEO and Founder

Jeff Galvin

CEO and
Founder

Jeff earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies.

David Pauza, PhD<br/>
Chief Science Officer

C. David Pauza, PhD

Chief Science
Officer

David has 35 years of experience in HIV, immunology, virology, and cancer biology, and has held faculty positions and at University of Wisconsin and University of Maryland medical schools. Prior to joining AGT, David was Adjunct Professor of Medicine at the University of Maryland Medical School in Baltimore.

neil-lyons-large

C. Neil Lyons, CPA

Chief Financial Officer &
Executive Vice President

Neil has more than 30 years of experience in finance, strategy, raising capital, SEC compliance, and corporate governance in both public and private companies, with over 10 years of that leading finance for publicly-traded, clinical-stage biotechnology companies.

Irene-Tennant-large

Irene Tennant, M.Sc.

Director,
Clinical Development

Irene brings more than 20 years of experience in clinical research and operations, and has led teams in support of the development of biopharma products and pharmaceutical first in class treatments in gene medicine, oncology, and infectious diseases.

kelly-huang-large

Kelly Huang, PhD

Director, Preclinical
Product Development

Kelly brings more than 10 years of experience in biopharma drug development, and has lead teams to support the development of drugs targeting diverse therapeutic areas including infectious disease, autoimmunity, and oncology.

AGT's Core Objectives

Leverage our lentivirus platform to create highly-effective targeted genetic medicines
Create solutions for patients across a spectrum of infectious diseases, cancers and inherited disorders
Collaborate with leading medical researchers from around the globe
Partner with pharmaceutical and biotech firms on indication and platform-specific opportunities
Enhance our proprietary platform to expedite drug development